Technical Analysis for NBRV - Nabriva Therapeutics AG

Grade Last Price % Change Price Change
grade C 2.38 6.73% 0.15
NBRV closed up 6.73 percent on Friday, May 24, 2019, on 45 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical NBRV trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Fell Below 200 DMA Bearish 6.73%
Wide Bands Range Expansion 6.73%
MACD Bearish Signal Line Cross Bearish 0.85%
180 Bearish Setup Bearish Swing Setup 0.85%
NR7 Range Contraction 0.85%
Inside Day Range Contraction 0.85%
Wide Bands Range Expansion 0.85%
200 DMA Support Bullish -2.86%

Older signals for NBRV ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections. The company is developing intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia; and intends to develop lefamulin for additional indications other than pneumonia. It also develops BC-7013, a topical pleuromutilin antibiotic, which has completed a Phase 1 clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria.
Chemistry Pharmaceutical Industry Chemical Compounds Organic Compounds Antibiotics Alcohols Antibiotic Infections Skin And Skin Structure Infections Pneumonia Community Acquired Bacterial Pneumonia Thioethers
Is NBRV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 25 INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 24 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - NBRV
May 24 KushCo Holdings, Inc. (KSHB), Nabriva Therapeutics PLC (NBRV), Equity Bancshares, Inc. (EQBK) -  Bronstein, Gewirtz & Grossman, LLC Class Action
May 24 KushCo Holdings, Inc. (KSHB), Nabriva Therapeutics PLC (NBRV), Equity Bancshares, Inc. (EQBK) - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder
May 23 NABRIVA LAWSUIT FILED: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nabriva Therapeutics plc; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NBRV
May 22 NBRV DEADLINE: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Nabriva Therapeutics plc – NBRV
May 22 Pomerantz Law Firm Announces the Filing of a Class Action against Nabriva Therapeutics plc and Certain Officers – NBRV
May 22 KushCo Holdings, Inc. (KSHB), Nabriva Therapeutics PLC (NBRV), Equity Bancshares, Inc. (EQBK) - Bronstein, Gewirtz & Grossman, LLC Announces Class Action
May 22 Nabriva Therapeutics to Present at the Jefferies 2019 Healthcare Conference
May 21 SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
See more NBRV news...
Indicators
Indicator Value
52 Week High 4.68
52 Week Low 1.12
Average Volume 1,459,259
200-Day Moving Average 2.3371
50-Day Moving Average 2.6678
20-Day Moving Average 2.4625
10-Day Moving Average 2.511
Average True Range 0.1945
ADX 16.38
+DI 21.2646
-DI 27.7306
Chandelier Exit (Long, 3 ATRs ) 2.4865
Chandelier Exit (Short, 3 ATRs ) 2.6035
Upper Bollinger Band 2.9512
Lower Bollinger Band 1.9738
Percent B (%b) 0.42
BandWidth 39.691371
MACD Line -0.0638
MACD Signal Line -0.0461
MACD Histogram -0.0177
Fundamentals Value
Market Cap 63.88 Million
Num Shares 26.8 Million
EPS -11.49
Price-to-Earnings (P/E) Ratio -0.21
Price-to-Sales 24.71
Price-to-Book 3.00
PEG Ratio -0.04
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.62
Resistance 3 (R3) 2.60 2.50 2.58
Resistance 2 (R2) 2.50 2.44 2.51 2.57
Resistance 1 (R1) 2.44 2.40 2.47 2.46 2.55
Pivot Point 2.34 2.34 2.36 2.35 2.34
Support 1 (S1) 2.28 2.28 2.31 2.30 2.21
Support 2 (S2) 2.18 2.24 2.19 2.19
Support 3 (S3) 2.12 2.18 2.18
Support 4 (S4) 2.14